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Abstract
Several species of β-amyloid peptides (Aβ) exist as a result of differential cleavage from amyloid precursor protein (APP)
to yield various C-terminal Aβ peptides. Several N-terminal modified Aβ peptides have also been identified in
Alzheimer’s disease (AD) brains, the most common of which is pyroglutamate-modified Aβ (AβpE3-42). AβpE3-42 peptide
has an increased propensity to aggregate, appears to accumulate in the brain before the appearance of clinical
symptoms of AD, and precedes Aβ1-42 deposition. Moreover, in vitro studies have shown that AβpE3-42 can act as a seed
for full length Aβ1-42. In this study, we characterized the Drosophila model of AβpE3-42 toxicity by expressing the peptide
in specific sets of neurons using the GAL4-UAS system, and measuring different phenotypic outcomes. We found that
AβpE3-42 peptide had an increased propensity to aggregate. Expression of AβpE3-42 in the neurons of adult flies led to
behavioural dysfunction and shortened lifespan. Expression of AβpE3-42 constitutively in the eyes led to disorganised
ommatidia, and activation of the c-Jun N-terminal kinase (JNK) signaling pathway. The eye disruption was almost
completely rescued by co-expressing a candidate Aβ degrading enzyme, neprilysin2. Furthermore, we found that
neprilysin2 was capable of degrading AβpE3-42. Also, we tested the seeding hypothesis for AβpE3-42 in vivo, and measured
its effect on Aβ1-42 levels. We found that Aβ1-42 levels were significantly increased when Aβ1-42 and AβpE3-42 peptides
were co-expressed. Furthermore, we found that AβpE3-42 enhanced Aβ1-42 toxicity in vivo. Our findings implicate AβpE3-42
as an important source of toxicity in AD, and suggest that its specific degradation could be therapeutic.
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Introduction
Alzheimer’s Disease (AD) is a neurodegenerative dis-
order characterized by amyloid beta (Aβ) deposits and
neurofibrillary hyperphosphorylated tau tangles [1]. The
amyloid cascade, which has undergone some revision in
recent years, is the leading hypothesis for the pathology
associated with AD, and states that amyloidogenic Aβ is
the trigger of the pathogenic process leading to neuronal
cell death [2, 3]. Aβ induces several stressors, which
could lead to neuronal cell death [4]. The c-Jun N-
terminal kinase/stress-activated protein kinase (JNK/
SAPK) signaling pathway which influences cell death is
activated in response to many forms of stress, such as
oxidative stress and endoplasmic reticulum (ER) stress
[5, 6]. In particular, Aβ is able to activate the JNK/SAPK
pathway, and increased phosphorylation of JNK/SAPK
has been observed in post-mortem AD brain tissue in
comparison to control cases [5, 7].
Aβ peptides form as a cleavage product from the amyl-
oid precursor protein (APP) [8]. Several species of Aβ
peptides exist, as a result of differential cleavage from
APP to yield various C-terminal Aβ peptides. Aβ40 and
Aβ42 are the most abundant, with Aβ42 being the more
toxic form [9]. More recently, Aβ43 has also been identi-
fied as a pathogenic species [10, 11]. There are also
several N-terminal truncated/modified Aβ peptides that
have been identified in AD brains, the most common of
which is pyroglutamate-modified Aβ [12–14].
Pyroglutamic (pGlu) acid is generated from N-terminal
glutamine during pro-hormone maturation in the secretory
pathway; the enzyme glutaminyl cyclase (QC) is directed
to the secretory pathway and catalyses the conversion from
N-terminal glutamic to pGlu acid [15, 16]. Interestingly,
Aβ undergoes this post-translational modification at its
amino terminus, also catalyzed by QC [17], which is up-
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regulated in the cortex of patients with AD [18]. Of par-
ticular interest is the highly abundant AβpE3-42, which is
generated by cleavage of the first 2 amino acids of the Aβ
peptide, followed by pGlu-modification of glutamate in the
third amino acid position, which is thought to stabilize it
and/or promote its aggregation propensity [14].
Interestingly, water soluble Aβ, which appear before
plaques is made up predominantly of AβpE3-42 [19], and
indeed AβpE3-42 accumulate early on in the brain before
the appearance of clinical symptoms and Aβ1-42 depos-
ition [20–23]. Moreover, in vitro studies have shown that
AβpE3-42 has an increased propensity to aggregate in
comparison to Aβ1-42 and can act as a seed/primer for
full length Aβ1-42 [14, 24, 25]. AβpE3-42 behaves in a
prion-like manner, whereby only small quantities of
AβpE3-42 are able to increase the amount of metastable
low-n Aβ1-42 oligomers in vitro [25]. These attributes
have created a lot of interest in AβpE3-42 peptides, and
several groups have suggested that they are important in
initiating the pathological cascade of AD [14, 20].
Interestingly, AβpE3-42 plaque load has been observed
in brain autopsies of familial, sporadic cases and controls
although, importantly, oligomeric AβpE3-42 was only
found in the familial and sporadic cases [26]. There is
also a likely role for AβpE3-42 in intra-neuronal AD tox-
icity. A study that expressed AβQ3-42 under the Thy-1 pro-
moter in mice (glutamine was used instead of glutamate
because it is a better substrate for pyroglutamate conver-
sion, [15]) showed increased levels of intra-neuronal
AβpE3-42, severe neurological impairment and loss of
Purkinje cells [27]. Furthermore, AβpE3-42 expressing mice
which display neuronal loss [28], when crossed into a tau
KO background were almost completely protected against
neuronal loss, establishing a functional connection be-
tween pGluAβ and tau [25]. Moreover, transgenic mouse
models of AD that develop more severe pathology, as
measured by the appearance of early neurological pheno-
types and amyloid plaque deposition, tend to have high
levels of AβpE3-42 [14].
Over-expression or reduction of QC has also been
shown to exacerbate or rescue behavioural phenotypes and
plaque pathology in an AD mouse model [29]. Interest-
ingly, QC KO mice showed a reduction in both AβpE3-42
and Aβ1-42 levels, again supporting the idea that AβpE3-42
plays a role in seeding Aβ1-42 [29]. The data also demon-
strate the importance of QC, and suggest that a reduction
of QC might be a promising therapeutic strategy.
Many signaling pathways/molecules are conserved be-
tween flies and humans, and QC is 1 of them. Drosophila
has 2 QCs – Drome QC and isoDrome QC, which have
different subcellular locations [30]. IsoDrome QC more
closely resembles the mammalian homologue [30]. Inter-
estingly, treatment of AβQ3-42 transgenic flies with a QC
inhibitor led to reduced AβpE3-42 levels [18], highlighting
the usefulness of Drosophila to investigate the molecular
pathogenicity of AβpE3-42. Several labs have generated fly
models that express various Aβ peptides [31–33]. AβQ3-42
fly models are available, but have not been fully character-
ized or utilized to test the “seeding hypothesis”.
In this study, we characterized a Drosophila model of
AβpE3-42 toxicity in the fruit-fly. Expression specifically
in adult fly neurons led to behavioural dysfunction and
shortened lifespan. Expression of the AβpE3-42 constitu-
tively in the eyes led to disorganised ommatidia, which
was ameliorated by neprilysin2. Furthermore, we show
for the first time that neprilysin2 was able to degrade
pyroglutamate Aβ.
Several recent studies have suggested that AβpE3-42 can
act as a seed for Aβ1-42, and such a role has been dem-
onstrated in vitro. AβpE3-42 has been shown to increase
the amount of metastable low-n Aβ1-42 oligomers in
vitro [25]. Furthermore, peri-hippocampal injection of
AβpE3-42 into APPswe/NOS2-/- AD mice led to the pres-
ence of both AβpE3-42 and conventional Aβ plaques,
which the authors mention was hardly seen in sham
injected AD mice or WT mice injected with AβpE3-42
[25]. However, the direct effect of AβpE3-42 on Aβ1-42 in
vivo remains to be assessed, because the genetic back-
ground of the AD mouse lines are mutant for several
genes that may well be affected by AβpE3-42. Further-
more, to control for the specificity of the AβpE3-42 spe-
cies in causing enhanced plaque formation, an important
control of peri-hippocampal injection of Aβ1-42 into the
AD mice is missing from their studies.
We have utilized the Drosophila model to our advan-
tage by expressing multiple transgenes at the same time
to test this seeding hypothesis in vivo, and thus deter-
mine whether AβpE3-42 could be a target for therapeutic
intervention, and/or a diagnostic marker. We found that
total Aβ1-42 levels and toxicity are greatly increased
when AβpE3-42 is co-expressed. These data suggest that
AβpE3-42 is able to stabilise Aβ1-42 in vivo.
Materials and methods
Fly stocks and maintenance
All fly stocks were maintained either at 25 °C or 28 °C on
a 12:12-h light:dark cycle at constant humidity on a stand-
ard sugar-yeast (SY) medium (15gl-1 agar, 50 gl-1 sugar,
100 gl-1 autolysed yeast, 100gl-1 nipagin and 3 ml l-1 pro-
pionic acid). Adult-onset, neuronal-specific expression of
Aβ peptide was achieved by using the elav GeneSwitch
(elavGS)-UAS system. ElavGS was derived from the ori-
ginal elavGS 301.2 line [34] and obtained as a generous
gift from Dr H. Tricoire (CNRS, France), GMR driver was
from Bloomington stock centre. UAS-Aβ1-42 line was
obtained from Dr D. Crowther [35]. UAS- AβQ3-42 line
has been previously described [36], briefly the rat pre pro-
enkephalin signaling sequence was cloned upstream
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AβQ3-42 and put into the EcoR1 site of the pUAST vector,
the construct then gets processed via prohormone conver-
tases and glutaminyl cyclase to generate AβpE3-42 [17, 37]
(Additional file 1: Figure S1). GMR, elavGS and UAS-lines
used in all experiments were backcrossed six times into
the w1118 genetic background. Expression by elavGS was
induced by treatment with mifepristone (RU486; 200 μM)
added to the standard SY medium. In the absence of mife-
pristone (RU486; -RU), the transgene remains transcrip-
tionally silent. Following treatment with RU486, AβQ3-42
peptide is expressed.
Lifespan analyses
For all experiments, flies were raised at a standard dens-
ity on standard SY medium in 200 mL bottles. Two days
after eclosion once-mated females were transferred to
experimental vials containing SY medium with or with-
out RU486 (200 μM) at a density of 10 flies per vial (120
flies per genotype were used in Fig. 2, and 150 flies per
genotype were used in Fig. 4). Deaths were scored al-
most every other day and flies were transferred to fresh
food. Data are presented as survival curves and statistical
analysis was performed using log-rank tests to compare
survival of groups.
Negative geotaxis assays
Climbing assays were performed at 25 °C according to
previously published methods [31]. Climbing was ana-
lysed every 2–3 days post-RU486 treatment. Fifteen
adult flies were placed in a vertical column, then their
rate of climb to the top of the column was analysed.
Flies reaching the top (12 cm) and flies remaining at the
bottom of the column after a 30 s period were counted
separately, and 3 trials were performed for each experi-
ment. Scores recorded were the mean number of flies at
the top (ntop), the mean number of flies at the bottom
(nbottom) and the total number of flies assessed (ntot). A per-
formance index (PI) defined as ½(ntot + ntop - nbottom)/ ntot)
was calculated. Data are presented as the mean PI ± SEM
obtained in 3 independent experiments for each group,
and analyses of variances (ANOVA) were performed using
JMP software.
Quantification of Aβ peptide by ELISA
Quantification of Aβ was carried out as previously de-
scribed [38]. To extract total Aβ, 5 Drosophila heads
were homogenised in 50 μl GnHCl extraction buffer
(5 M Guanidine HCl, 50 mM Hepes pH 7.3, protease in-
hibitor cocktail (Sigma, P8340) and 5 mM EDTA), cen-
trifuged at 21,000 g for 5 min at 4 °C, and cleared
supernatant retained as the total fly Aβ sample. Alterna-
tively, for soluble and insoluble pools of Aβ, 25 fly heads
were homogenised in 50 μl tissue homogenisation buffer
(250 mM sucrose, 20 mM Tris base, 1 mM EDTA,
1 mM EGTA, protease inhibitor cocktail (Sigma) then
mixed further with 50 μl diethyl acetate (DEA) buffer
(0.4 % DEA, 100 mM NaCl and protease inhibitor cock-
tail). Samples were centrifuged at 135,000 g for one hour
at 4 °C (Beckman OptimaTM Max centrifuge, TLA120.1
rotor), and supernatant retained as the cytosolic, soluble
Aβ fraction. Pellets were resuspended in 200 μls ice-cold
formic acid (FA; 70 %), and sonicated. Samples were re-
centrifuged at 135,000 g for one hour at 4 °C, then
100 μl of supernatant diluted with 1 ml FA neutralisa-
tion buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05 %
NaN3) and retained as the insoluble, formic acid-
extractable Aβ fraction. Aβ content was measured using
the hAmyloid β42 ELISA kits, X-42 and N3pE-42 (IBL
INTERNATIONAL). N of 3 or 4 individual samples
were diluted in sample/standard dilution buffer and
ELISA performed according to the manufacturers’ in-
structions. Protein extracts were quantified using the
Bradford protein assay (Bio-Rad protein assay reagent;
Bio-Rad laboratories (UK) Ltd) and the amount of Aβ in
each sample expressed as a ratio of the total protein
content (pmol/g total protein).
Western blotting
For total Aβ extraction, we used a procedure previously
described [11]. 20 heads per biological replicate were ho-
mogenized in 100 μL of 70 % formic acid. Samples were
centrifuged at 16,000 g for 20 min at room temperature.
The supernatant was collected and evaporated using a
SpeedVac. The pellet was resuspended in 100 μL 2×
LDS containing reducing agent (Invitrogen) and homog-
enized by sonication (10 pulses). Samples were then
boiled at 100 °C for 10 min and 15 μL of each sample
were used for western blotting to determine total Aβ
levels. For LDS/SDS oligomer Aβ extraction, 20 heads
per biological replicate were homogenized in 100 μL 2×
LDS containing reducing agent (Invitrogen). Samples
were incubated on ice for 30 min and then boiled at
100 °C for 10 min. 15 μL per sample were used for west-
ern blotting to evaluate LDS/SDS-stable Aβ oligomers.
Proteins were separated on 16.5 % Tris-Tricine Criterion
gels (Biorad) blotted onto nitrocellulose membranes.
Membranes were incubated in a blocking solution con-
taining 5 % milk proteins in TBST for 1 h at room
temperature, then probed with primary antibody diluted
in TBST + 5 % BSA overnight at 4 °C. 82E1 Aβ1-42
Antibody was from Takara, used at 1 in 100 dilution.
For pJNK western blot analyses, total protein was ex-
tracted from 5 fly heads in 30 μl 2 × LDS buffer contain-
ing reducing agent (Invitrogen). Membranes were
incubated in a blocking solution containing 5 % BSA in
TBST for 1 h at room temperature, then probed with
primary antibody diluted in TBST + 5 % BSA overnight
at 4 °C. mouse monoclonal phospho-SAPK/JNK (T183/
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Y185) antibody was from cell signaling, used at 1 in
1000 dilution. Rabbit polyclonal actin antibody was from
abcam and used at 1 in 1000 dilution.
Quantitative RT-PCR
Total RNA was extracted from 20 to 25 fly heads using
TRIzol (GIBCO) according to the manufacturers’ instruc-
tions. The concentration of total RNA purified for each
sample was measured using an Eppendorf biophotometer.
1 μg of total RNA was then subjected to DNA digestion
using DNAse I (Ambion), immediately followed by reverse
transcription using the Superscript II system (Invitrogen)
with oligo(dT) primers. Quantitative PCR was performed
using the PRISM 7000 sequence-detection system (Ap-
plied Biosystems), SYBR Green (Molecular Probes), ROX
Reference Dye (Invitrogen), and Hot StarTaq (Qiagen,
Valencia, CA) by following manufacturers’ instructions.
Each sample was analysed at a minimum in triplicate with
both target gene (AβQ3-42 or NEP2) and control gene
(RP49) primers in parallel. The primers for the Aβ trans-
genes were directed to the 5’ end and 3’ end of the Aβ
coding sequence: forward CGACATGACTCAGGTTAT
GAAGTT; reverse GACAACGCCCACCAT Neprily-
sin2 primers are, forward ACGAGGTCAACTGGATG
GAC and reverse GTCGAGCTTGGCGTAGTAGG. RP49
primers were as follows: forward ATGACCATCCGCCC
AGCATCAGG; reverse ATCTCGCCGCAGTAAACG.
Eye phenotype
Eye images of 2/3-day-old female flies expressing AβpE3-42
under the control of the GMR-Gal4 driver at 28 °C were
taken. Nail polish imprint of the external eye was carried
out as previously described. For adult eye transverse
sections, adult heads were fixed, dehydrated, sectioned
(10 microns thick) and stained with Harry’s hematoxylin.
To investigate the eye phenotype of double transgenic
Aβ1-42; AβQ3-42 flies, we kept the flies at 25 °C to minimize
AβpE3-42 eye phenotype. Images were taken with ZEISS
Axioskop2 plus microscope. The eye phenotype was
quantified by assigning numbers, from zero to 2 to indi-
vidual flies chosen at random. Normal looking eyes were
given zero, flies with moderate eye phenotype were
assigned 1, and flies with strong eye phenotype were given
2, (N = 5 − 6 flies per genotype). The scoring was carried
out blind by 2 independent researchers.
Statistical analyses
For lifespan analyses, log-rank tests were used to assess
for statistical differences. Eye phenotype was presented
as means ± SEM, and statistically assessed by Student’s t
test. Other data are presented as means ± SEM obtained
in at least 3 independent experiments, and differences
between means were assessed by either Student’s t test
or 2-way analysis of variance (ANOVA) using JMP
(version 12.0) software (SAS Institute, Cary, NC, USA).
Results
Pyroglutamate Aβ (AβpE3-42) expression can be induced in
the adult Drosophila nervous system
A fly model that expresses AβE3-42 has been described
[39], however, we are utilising a previously generated
AβQ3-42 transgenic fly model for this study, since glu-
tamine is a better substrate for pyroglutamate conver-
sion than glutamate [14]. AβQ3-42 fly models have been
generated but little characterized [18, 36]. To ensure
that these flies could express AβQ3-42, we drove expres-
sion of the AβQ3-42 transgene in adult neurons with the
inducible pan-neuronal driver, elav GeneSwitch (elavGS)
[31, 34]. We measured RNA levels of AβQ3-42 flies in
adult neurons, after treating elavGS;UAS-AβQ3-42 flies
with the activator mifepristone (RU486) for 7 days, start-
ing at 2 days post-eclosion (Fig. 1a). We found a signifi-
cant increase in AβQ3-42 transcripts in RU486-treated
elavGS;UAS-AβQ3-42 flies in comparison to untreated flies
(Fig. 1a). Furthermore, we confirmed that the flies gener-
ate pyroglutamate-modified Aβ by measuring AβpE3-42
protein levels specifically. AβpE3-42 protein levels in adult
neurons of elavGS;UAS-AβQ3-42 flies treated with RU486
for 21 days, starting at 2 days post-eclosion were signifi-
cantly increased in comparison to untreated flies (Fig. 1b).
These data demonstrate that AβpE3-42 can be successfully
generated in the flies.
Expression of AβpE3-42 causes shortened lifespan,
neuronal dysfunction, disorganised eye phenotype, and
activates JNK in Drosophila
To determine whether expression of AβpE3-42 in neurons
is toxic, we used the elavGS driver to express AβpE3-42
peptide in adult neurons, and measured the effects on
behaviour. Impaired geotaxis is a behavioural measure of
neuronal dysfunction and can be assessed using a climb-
ing assay [31]. elavGS;UAS-AβQ3-42 flies were treated
with RU486 starting at 2 days post-eclosion, and their
climbing ability was subsequently recorded. Flies ex-
pressing AβpE3-42 displayed substantially increased rate
of decline in negative geotaxis with age in comparison to
the –RU or driver (elavGS) alone control flies (Fig 2a
and Additional file 2: Figure S2).
We also measured the effects of AβpE3-42 on lifespan in
comparison to the –RU control flies, by treating elavG-
S,UAS-AβQ3-42 flies with RU486 starting at 2 days post-
eclosion and recording their subsequent survival. Expression
of AβpE3-42 in adult neurons significantly shortened median
(54 %) and maximum lifespan (31 %) in comparison to con-
trol elavGS,UAS-AβQ3-42 -RU flies (Fig. 2b).
To assess the effects of AβpE3-42 on neurodegenera-
tion, we expressed AβpE3-42 constitutively in the fly eye
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using the GMR-GAL4 driver and observed the effect on
the organization of the ommatidia, an assay that has
been used extensively to characterise fly models of
neurodegenerative diseases [35]. Expression of AβpE3-42
caused disorganisation of the ommatidia in these flies,
presenting with eye roughness and fused ommatidia in
comparison to flies expressing EGFP, and w1118 control
flies (Fig. 2c).
The JNK/SAPK signaling pathway which influences
cell death is activated by Aβ, and has been suggested to
contribute to Aβ mediated cell death in fly models ex-
pressing Aβ1-42 [40, 41]. To determine whether AβpE3-42
expressing flies are also capable of activating JNK, we
measured the levels of phosphorylated JNK as a read-out
in the flies, by western blot analyses. We found a signifi-
cant increase in the level of phosphorylated JNK in flies
expressing AβpE3-42 (GMR-GAL4/+; AβQ3-42/+) in com-
parison to control flies expressing LACZ (GMR-GAL4/
LACZ), 6 days post-eclosion (Fig. 2d).
Co-expression of neprilysin2 suppresses the toxicity of
AβpE3-42 expressing flies
Neprilysin (NEP) and its close homologue Neprilysin2
(Nep2) are candidate Aβ degrading enzymes, and
regulate amyloid protein levels in AD [42–44]. We next
determined whether the fly orthologue, nep2, which has
been shown previously to significantly reduce Aβ1-42
levels and toxicity, is able to similarly ameliorate
AβpE3-42 induced toxicity. We made use of the rough
eye/disorganised ommatidia phenotype, and found that
co-expression of NEP2 using the EP(3)3549 Drosophila
strain, with the GMR-GAL4 driver almost completely
suppressed both the external disorganised ommatidia and
internal retinal degeneration of the AβpE3-42 expressing
flies (Fig. 3a). We confirmed that the EP(3)3549 strain
had a significant expression of NEP2 levels by RTPCR
(Additional file 3: Figure S3A).
Co-expression of neprilysin2 reduces AβpE3-42 protein
levels
To understand the mechanism by which NEP2 amelio-
rates the AβpE3-42 eye phenotype, we measured total Aβ
load, and AβpE3-42 protein levels specifically in the flies,
7 days post-eclosion. Interestingly, we found by ELISA
analyses that Aβ load and importantly, AβpE3-42 levels
were significantly reduced in flies co-expressing AβpE3-42
and NEP2 in comparison to flies co-expressing AβpE3-42
and EGFP as a control (Additional file 3: Figure S3B and
Fig. 3b). Furthermore, the reduction we see at the
protein level is not due to reduced RNA levels, since this
reduction was not observed in the RNA by RTPCR
analyses, 7 days post eclosion (Additional file 3: Figure
S3C). These data demonstrate a major role of NEP2 in
ameliorating AβpE3-42 induced toxicity, by reducing
AβpE3-42 protein levels.
AβpE3-42 is more toxic than Aβ1-42 in Drosophila
Data from mouse models have indicated that the appear-
ance of AβpE3-42 correlates with increased pathogenicity
[45]. To determine whether AβpE3-42 peptide was more
toxic in comparison to Aβ1-42, we needed 2 lines with
comparable levels of Aβ peptide. We expressed the
peptides with the elavGS driver line, by treating AβQ3-42
and Aβ1-42 transgenic flies independently with RU486
starting at 2 days post-eclosion, for 2 days and 21 days,
and measured Aβ protein levels in adult neurons, taking
advantage of an ELISA kit that recognizes an epitope in
the middle of both AβpE3-42 and Aβ1-42 peptides. We
Fig. 1 Pyroglutamate Aβ expression in the Drosophila nervous system.
a RNA levels were quantified at 7 days post-RU486 treatment and
(b) AβpE3-42 protein levels were quantified at 21 days post-RU486
treatment. Data are presented as means ± SEM and were analysed by
Student t test, *P < 0.001 comparing Aβ RNA and protein expression in
RU486-treated elavGS/UAS-AβQ3-42 flies to their –RU486 controls
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found similar levels of total Aβ protein in the AβpE3-42
and Aβ1-42 expressing flies (Fig. 4a and b). However, the
solubility/aggregation propensity of Aβ differed between
the AβpE3-42 and Aβ1-42 expressing flies, with AβpE3-42
expressing flies having a significantly increased ratio of
insoluble to total Aβ in comparison to Aβ1-42 expressing
flies (Fig. 4c). AβpE3-42 expressing flies also suffered in-
creased toxicity, because expression of AβpE3-42 in adult
neurons significantly shortened median (27 %) and max-
imum (23 %) lifespan in comparison both to control
w1118;;elavGS and Aβ1-42 expressing flies (Fig. 4d), dem-
onstrating a more toxic effect of the AβpE3-42 peptide.
Fig. 2 Expression of AβpE3-42 causes locomotor dysfunction, shortened lifespan, eye disruption, and JNK activation in Drosophila. a Climbing
ability of elavGS/UAS-AβQ3-42 flies on + and – RU486 SY medium were assessed at the indicated time-points. Data are presented as the average
performance index (PI) ± SEM and were compared using 2-way ANOVA (number of independent tests (n) = 3 *P < 0.001 (b) Expression of AβpE3-42
in adult neurons shortens lifespan. Survival curves are depicted and data were compared using the log-rank test, *P < 0.001 comparing elavGS/
UAS-AβQ3-42 + RU flies to -RU flies. c Expression of AβpE3-42 causes a neurodegenerative eye phenotype. First 2 images from left to right are light
microscopy images and latter 2 images are nail varnish imprints of eyes (magnification is 25×, and 40× objectives for close up images). From left
to right, GMR-GAL4/UAS-EGFP, GMR-GAL4/+;UAS-AβQ3-42/+, GMR-GAL4/+, GMR-GAL4/+;UAS-AβQ3-42/+. Note compressed and fused ommatidia in
AβQ3-42 expressing flies in comparison to control flies (GMR-GAL4/UAS-EGFP or GMR-GAL4/+). Flies were grown at 28 °C. d Expression of AβpE3-42
increases the levels of phosphorylated JNK. Data are presented as means ± SEM and were analysed by Student t test, *P < 0.05 comparing
GMR-GAL4/+;UAS-AβQ3-42/+ flies to control GMR-GAL4/UAS-LACZ flies
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pGluAβ increases accumulation of Aβ in vivo
AβpE3-42 has been shown to increase the amount of
metastable low-n Aβ1-42 oligomers in vitro [25]. To study
in vivo, the seeding effect of AβpE3-42, we co-expressed
AβpE3-42 and Aβ1-42 peptides directly and compared the
effects to those seen in flies expressing Aβ1-42. We
expressed Aβ1-42 or AβpE3-42 constitutively with the GMR-
GAL4 driver line, and measured at 2−3 days post-eclosion
total protein levels of flies expressing either peptide. We
found a substantial increase in insoluble Aβ levels and a
significant decrease in soluble Aβ detected in AβpE3-42
expressing flies in comparison to Aβ1-42 expressing flies
with ELISA (Fig. 5a). There was also a significant increase
in total Aβ levels in Aβ1-42; AβpE3-42 expressing flies in
comparison to Aβ1-42;Aβ1-42 expressing flies (Fig. 5a and
Additional file 4: Figure S4). Furthermore, we found a shift
in Aβ solubility in Aβ1-42; AβpE3-42 expressing flies, with a
significant decrease in soluble Aβ and a substantial in-
crease in insoluble Aβ in comparison to Aβ1-42;Aβ1-42
expressing flies (Fig. 5a).
We next investigated the effect of co-expressing Aβ1-42;
AβpE3-42 specifically on Aβ1-42 stability, and whether this
contributed to the increased total Aβ levels. We measured
Aβ1-42 levels by western blot, by selecting an antibody that
detects Aβ1-42, but not AβpE3-42 (Fig. 5b and Additional
file 5: Figure S5). Flies co-expressing Aβ1-42; AβpE3-42 had
increased levels of Aβ1-42 levels in comparison to flies ex-
pressing a single copy of Aβ1-42, which do not accumulate
enough protein levels for quantification by western blot
analyses (Fig. 5a and Additional file 5: Figure S5). How-
ever, Aβ1-42 was specifically detected in flies containing 2
copies of the Aβ1-42 transgene (Aβ1-42;Aβ1-42), confirming
protein expression of this line with the antibody (Fig. 5b).
Interestingly, the flies co-expressing Aβ1-42;Aβ1-42 signifi-
cantly expressed lower levels of Aβ1-42 in comparison to
flies co-expressing Aβ1-42; AβpE3-42 (Fig. 5b).
pGluAβ enhances Aβ toxicity
Since AβpE3-42 increased the stability of Aβ1-42, we
assessed whether it also increased the toxicity of Aβ1-42,
using the rough eye/disorganised ommatidia phenotype.
Flies co-expressing Aβ1-42; AβpE3-42, but not those ex-
pressing Aβ1-42;Aβ1-42 presented with disorganised om-
matidia, 2 days post eclosion, and this phenotype was
stronger than in flies expressing AβQ3-42 alone (Fig. 5c
and Additional file 6: Figure S6) suggesting that AβpE3-42
enhances the toxicity of Aβ1-42.
Collectively, these data suggest that AβpE3-42 is able to
increase the stability of the Aβ1-42 peptide and exacerbate
its toxicity in vivo.
Discussion
AβpE3-42 is increasingly thought to play a pivotal role in
the pathogenesis of Alzheimer’s disease [14]. Although
previous studies in vitro have suggested that AβpE3-42
acts as a seed for Aβ stability, and some correlative work
has been done in vivo [25], this seeding behaviour and
its consequences have not been examined in vivo. Our
study demonstrates that AβpE3-42 increases the levels of
Aβ1-42, presumably by increasing its stability, and that it
enhances toxicity of the Aβ1-42 peptide, as observed in
flies co-expressing AβpE3-42 and Aβ1-42 in comparison to
flies expressing 2 copies of Aβ1-42.
Fig. 3 a Co-expression of neprilysin2 suppresses the toxicity of AβpE3-42
expressing flies. Top, light microscopy images and bottom, transverse
sections. From left to right, GMR-GAL4/UAS-EGFP;UAS-AβQ3-42/+ and
GMR-GAL4/UAS-EGFP;UAS-AβQ3-42/NEP2 (EP(3)3549). Flies were grown
at 28 °C. b Neprilysin2 significantly reduces AβpE3-42 protein levels,
*P < 0.001. AβpE3-42 levels were quantified by ELISA. Data are presented
as means ± SEM and were analysed by Student t test
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First, we characterized the model. Expression of the
AβpE3-42 peptide specifically in adult fly neurons led to
behavioural dysfunction and shortened lifespan, and
constitutive expression in the eyes led to disorganised
ommatida. Furthermore, we found that AβpE3-42 was
able to activate the JNK signaling pathway, suggesting a
role for this cell death activating pathway in AβpE3-42
mediated toxicity.
Interestingly, we found that we could ameliorate the
AβpE3-42 toxicity by over expressing Neprilsyin2. Increas-
ing the expression of several candidate in vivo Aβ
degrading enzymes, such as NEP or Insulin degrading
enzyme (IDE) have been shown to reduce the cerebral
amyloid plaque burden observed in APP over-expressing
mice [46]. However, direct interactions between AβpE3-42
and Neprilysin have not been investigated. We found
that over-expression of Drosophila NEP2 was able to re-
duce AβpE3-42 levels and improve considerably the disor-
ganised ommatidia, demonstrating for the first time that,
although AβpE3-42 may aggregate more than Aβ1-42, NEP2
is capable of degrading pyroglutamate-modified Aβ.
Also, we found that these flies had an increase in the
ratio of insoluble to total Aβ levels in comparison to flies
expressing Aβ1-42, confirming the propensity of AβpE3-42
Fig. 4 AβpE3-42 is more toxic than Aβ1-42 in Drosophila. Following treatment with RU486, Aβ1-42 and AβpE3-42 peptides were expressed at similar
levels, quantified at 2 days and 21 days post-RU486 treatment (a) and (b) respectively. c A significant increase in the amount of insoluble to total Aβ
protein levels in AβpE3-42 expressing flies in comparison to Aβ1-42 expressing flies was observed when quantified at 21 days post-RU486 treatment.
Data are presented as means ± SEM and were analysed by Student’s t test, P < 0.01. d Expression of AβpE3-42 specifically in adult neurons shortens
lifespan significantly relative to both Aβ1-42 and w1118 control. Survival curves are depicted and data were compared using the log-rank test.
*P < 0.001 comparing elavGS/UAS-AβQ3-42 + RU flies to elavGS/+ and UAS-Aβ1-42 /+;elavGS/+ +RU flies
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to aggregate as previously described [14]. Furthermore, we
found that AβpE3-42 was more toxic than Aβ1-42 peptide.
Another interesting finding from our analyses is the
increase in Aβ levels observed in response to AβpE3-42.
We found a general increase in total Aβ levels in flies
co-expressing AβpE3-42 and Aβ1-42, and there was also an
increase in the ratio of insoluble Aβ to total Aβ levels in
these flies. To determine what role Aβ1-42 might have in
this, we measured Aβ1-42 levels specifically by western
blot analyses. Interestingly, we found that total Aβ1-42
levels were increased when AβpE3-42 was co-expressed.
Nussbaum et al. showed that Aβ peptides oligomerise by
different pathways, and that the low-n oligomers of
AβpE3-42 are structurally distinct from Aβ1-42, and far more
cytotoxic, in the order of AβpE3-42 /Aβ1-42 > AβpE3-42 >
Aβ1-42 [25]. We found that co-expressing 1 copy each of
Aβ1-42 and AβpE3-42 increased the accumulation of Aβ1-42,
and was more toxic than expressing 2 copies of Aβ1-42,
Fig. 5 pGluAβ increases accumulation of Aβ in vivo, and exacerbates toxicity (a). Flies expressing Aβ1-42 had significantly more soluble Aβ,
P <0.05 but less insoluble Aβ, P <0.0001 in comparison to flies expressing AβpE3-42. Flies co-expressing Aβ1-42 and AβpE3-42 had significantly more
insoluble Aβ, P <0.01 but less soluble Aβ P <0.05 Aβ in comparison to flies co-expressing Aβ1-42 and Aβ1-42. Data are presented as means ± SEM
and were analysed by Student’s t-test. b There was a significant increase in Aβ1-42 accumulation in flies co-expressing Aβ1-42;AβpE3-42 in comparison to
flies expressing either a single copy of Aβ1-42 (expressing one single copy of Aβ1-42 does not accumulate enough protein levels for quantification by
western blot analyses), or flies expressing 2 copies of Aβ1-42, P < 0.05. Data are presented as means ± SEM and were analysed by Student’s t test.
GMR-GAL4/+;UAS-Aβ1-42/+, GMR-GAL4/+;UAS-AβQ3-42/+, GMR-GAL4/UAS-Aβ1-42;UAS-Aβ1-42/+ and GMR-GAL4/+;UAS-Aβ1-42/UAS-AβQ3-42 flies were
used for (a) and (b). c. Co-expression of Aβ1-42 and AβpE3-42 led to a disorganized eye phenotype that was absent in flies co-expressing Aβ1-42 and
Aβ1-42, and worse than in AβpE3-42 expressing flies. From left to right, GMR-GAL4/+;UAS-AβQ3-42/+, GMR-GAL4/UAS-Aβ1-42;UAS-Aβ1-42/+ and
GMR-GAL4/+;UAS-Aβ1-42/UAS-AβQ3-42 flies. Flies were grown at 25 °C
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indicating that AβpE3-42 is able to stabilise Aβ1-42 in a
different manner to over expressing the Aβ1-42 peptide,
perhaps by affecting its structure.
Conclusions
We have tested and validated the AβpE3-42 seeding hy-
pothesis and shown that indeed AβpE3-42 increases the
levels of Aβ, and that AβpE3-42 enhances pathology in
this AD model. These results raise AβpE3-42 as both a
potential biomarker and new therapeutic target in AD.
Furthermore, because Drosophila does not inherently
express Aβ, the observation that expression of AβpE3-42 is
able to cause toxicity independent of its effect on Aβ1-42
suggests that it is capable of initiating toxicity in other
ways. It would be interesting to uncover downstream
pathways that are modulated specifically by AβpE3-42, and
the fly provides a powerful context for pursuing this ques-
tion with genetic screens.
Additional files
Additional file 1: Figure S1. Generation of AβpE3-42. The proenkephalin
signaling peptide upstream of AβQ3-42 is cleaved by prohormone convertases,
AβQ3-42 is then released, and glutaminyl cyclase catalyses its conversion to
AβpE3-42. (PDF 271 kb)
Additional file 2: Figure S2. Expression of AβpE3-42 causes locomotor
dysfunction. Climbing ability of elavGS/UAS-AβQ3-42and elavGS flies on +
RU486 SY medium was assessed at the indicated time-points (see Materials
& Methods). Expression of AβpE3-42 in adult neurons reduced climbing ability
of the flies in comparison to control elavGS driver flies. Data are presented
as the average performance index (PI) ± SEM and were compared using
2-way ANOVA (number of independent tests (n) = 3 P < 0.01. (PDF 306 kb)
Additional file 3: Figure S3. (A). Confirming the expression of
Neprilysin 2 in the EP(3)3549 fly strain. There was a significant increase in
nep2 transcript levels in the flies expressing the EP(3)3549 EP element, in
comparison to the control fly lines expressing LACZ. Data are presented
as means ± SEM and were analysed by student’s t-test, P < 0.001. (B)
Neprilysin2 significantly reduces Aβ protein levels, *P < 0.001. AβX-42 levels
were quantified by ELISA. Data are presented as means ± SEM and were
analysed by Student t test. (C) Neprilysin2 does not reduce AβQ3-42 RNA
levels. There was a significant increase in AβQ3-42 RNA levels in flies
co-expressing AβQ3-42 and NEP2 in comparison to flies expressing AβQ3-42
and EGFP, by quantitative RTPCR, P < 0.01, student’s t-test. GMR-GAL4 was
used to drive expression of AβQ3-42 transgenic flies. (PDF 369 kb)
Additional file 4: Figure S4. pGluAβ increases accumulation of Aβ in
vivo. Flies co-expressing Aβ1-42 and AβpE3-42 peptide, had significantly
higher Aβ levels than flies co-expressing Aβ1-42 and Aβ1-42. Data are
presented as means ± SEM and were analysed by student’s t-test,
P < 0.01. GMR-GAL4 was used to drive expression of Aβ1-42 and AβQ3-42
transgenic flies. (PDF 417 kb)
Additional file 5: Figure S5. pGluAβ increases accumulation of Aβ1-42
in vivo. (A). Flies co-expressing Aβ1-42 and AβpE3-42 peptide, had substantially
more Aβ1-42 levels than flies expressing Aβ1-42 alone. Aβ was not detected
in flies expressing a single copy of Aβ1-42 because it does not accumulate
enough protein. However, Aβ1-42 was detected in flies expressing 2 copies of
Aβ1-42 (B), confirming protein expression in these flies with the antibody.
Furthermore, to validate specificity, Aβ1-42 was not detected in flies expressing
either a single copy or double copy of AβpE3-42. GMR-GAL4 was used to drive
expression of Aβ1-42 and AβQ3-42 transgenic flies. (PDF 10727 kb)
Additional file 6: Figure S6. Blind scoring of disorganised eye phenotype.
The data demonstrate a significant difference in the degree of severity of eye
roughness in flies co-expressing Aβ1-42 and AβpE3-42 in comparison to flies
expressing either 2 copies of Aβ1-42 (A), or AβpE3-42 only (B), *P < 0.001 for
both. Flies were grown at 25 °C. Data are presented as means ± SEM and
were analysed by Student’s t test. GMR-GAL4 was used to drive expression of
Aβ1-42 and AβQ3-42 transgenic flies. (PDF 303 kb)
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